^
    7d
    Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Xiangya Hospital of Central South University
    New trial
    |
    AiSuDa (ivarmacitinib)
    10d
    A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Xijing Hospital
    New trial
    |
    AiSuDa (ivarmacitinib)
    22d
    A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo (clinicaltrials.gov)
    P2, N=176, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    AiSuDa (ivarmacitinib)
    2ms
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study on the Efficacy and Safety of JAK1 Inhibitor Ivarmacitinib in Combination with Topical Corticosteroids in the Treatment of Moderate-to-Severe Chronic Hand Eczema (ChiCTR2500109549)
    P4, N=80, Not yet recruiting, The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    2ms
    Ivarmacitinib for the Treatment of Sjögren’s Syndrome (ChiCTR2500108666)
    P4, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    2ms
    Efficacy and Safety of Ivarmacitinib Sulfate Tablets in the Treatment of SAPHO Syndrome: A Single-Arm, Single-Center, Open-Label Clinical Trial (ChiCTR2500108339)
    P4, N=20, Not yet recruiting, The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    4ms
    A Prospective, Multicenter Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis(IMPROVE-RA) (ChiCTR2500106834)
    P4, N=1000, Not yet recruiting, Nanjing DrumTower Hospital of Nanjing University Medical School; Nanjing DrumTower Hospital of Nanjing University Medical School
    New P4 trial
    |
    CRP (C-reactive protein)
    |
    AiSuDa (ivarmacitinib)
    4ms
    JAK1 inhibitor combined with Camrelizumab as first-line therapy for PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR2500106336)
    P2, N=30, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    4ms
    Efficacy and Safety of Ivarmacitinib in Patients with Polymyalgia Rheumatica: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study (ChiCTR2500105703)
    P4, N=80, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    4ms
    A Multi-Center, Randomized, Controlled Trial of Ivarmacitinib in IgG4-Related Disease (ChiCTR2500105444)
    P4, N=88, Not yet recruiting, Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital Affiliated to Capital Medical University
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    4ms
    A prospective phase II clinical trial evaluating the efficacy and safety of chemotherapy combined with immune checkpoint inhibitors and ivarmacitinib in first-line treatment of extensive stage small cell lung cancer (ChiCTR2500104514)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial • Checkpoint inhibition
    |
    AiSuDa (ivarmacitinib)
    4ms
    A prospective clinical study on advanced or metastatic non-small cell lung cancer in the first-line treatment of adebelimab combined with emacetinib +/- chemotherapy (ChiCTR2500103941)
    P4, N=68, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiLi (adebrelimab) • AiSuDa (ivarmacitinib)